| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 36415 |
Collection of venous blood by venipuncture |
79,310 |
61,672 |
$6.31M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
44,386 |
41,871 |
$4.76M |
| 80048 |
Basic metabolic panel (calcium, ionized) |
50,678 |
39,133 |
$3.86M |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
10,120 |
8,731 |
$3.25M |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
38,689 |
37,330 |
$3.24M |
| 80053 |
Comprehensive metabolic panel |
55,927 |
46,127 |
$3.22M |
| J7030 |
Infusion, normal saline solution , 1000 cc |
14,147 |
10,459 |
$2.77M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
46,171 |
15,506 |
$2.61M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
2,129 |
2,028 |
$2.36M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
10,401 |
9,771 |
$1.76M |
| 87070 |
|
31,333 |
30,193 |
$1.47M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
16,643 |
15,701 |
$1.38M |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
15,340 |
13,989 |
$1.31M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
43,579 |
38,182 |
$1.21M |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
26,393 |
9,228 |
$1.20M |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
45,979 |
15,131 |
$1.11M |
| 81001 |
|
45,881 |
40,584 |
$990K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
24,762 |
9,227 |
$984K |
| 94060 |
|
2,577 |
2,500 |
$983K |
| 87486 |
|
3,984 |
3,832 |
$963K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
63,062 |
59,080 |
$933K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
8,217 |
6,833 |
$909K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
5,899 |
5,664 |
$861K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
20,822 |
14,508 |
$821K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
13,488 |
10,655 |
$783K |
| J3490 |
Unclassified drugs |
29,801 |
12,776 |
$779K |
| 82565 |
|
3,522 |
3,205 |
$767K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
2,387 |
2,309 |
$730K |
| 71046 |
Radiologic examination, chest; 2 views |
18,168 |
17,177 |
$664K |
| 87400 |
|
9,420 |
8,669 |
$656K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
409 |
391 |
$639K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
2,831 |
2,713 |
$637K |
| 82962 |
|
24,439 |
11,845 |
$574K |
| 93971 |
|
2,065 |
1,973 |
$509K |
| 77336 |
|
1,471 |
600 |
$480K |
| 71250 |
|
2,124 |
2,034 |
$443K |
| 81025 |
|
17,050 |
15,526 |
$408K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
16,084 |
13,428 |
$407K |
| 76830 |
Ultrasound, transvaginal |
3,605 |
3,507 |
$404K |
| 93922 |
|
1,248 |
1,211 |
$395K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
4,670 |
4,572 |
$372K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
12,018 |
9,634 |
$371K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
488 |
474 |
$367K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
2,318 |
2,247 |
$341K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
18,498 |
17,561 |
$320K |
| 73610 |
|
4,190 |
3,950 |
$308K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
39,880 |
32,616 |
$308K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
4,599 |
4,447 |
$295K |
| 70450 |
Computed tomography, head or brain; without contrast material |
9,952 |
9,083 |
$290K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
6,946 |
6,571 |
$290K |
| 93296 |
|
1,473 |
1,411 |
$262K |
| 92526 |
|
3,762 |
1,662 |
$257K |
| 73630 |
|
4,503 |
4,150 |
$254K |
| 94010 |
|
1,329 |
1,291 |
$252K |
| 95886 |
|
1,731 |
1,699 |
$251K |
| 36600 |
|
1,657 |
1,401 |
$247K |
| 93970 |
|
1,179 |
1,130 |
$245K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
544 |
530 |
$242K |
| 74018 |
|
7,301 |
6,999 |
$241K |
| 73130 |
|
3,399 |
2,917 |
$236K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
2,508 |
2,182 |
$231K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
2,040 |
2,027 |
$229K |
| J7050 |
Infusion, normal saline solution, 250 cc |
2,264 |
1,636 |
$222K |
| 94664 |
|
1,035 |
1,016 |
$221K |
| 73110 |
|
2,872 |
2,669 |
$219K |
| 82803 |
|
2,616 |
2,265 |
$219K |
| 71045 |
Radiologic examination, chest; single view |
22,849 |
19,747 |
$218K |
| 87088 |
|
34,097 |
30,720 |
$218K |
| 84702 |
|
7,947 |
6,101 |
$212K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
3,034 |
2,928 |
$204K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
4,109 |
3,887 |
$201K |
| 87077 |
|
15,720 |
13,862 |
$199K |
| 12001 |
|
1,007 |
982 |
$195K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
1,805 |
1,744 |
$194K |
| 73030 |
|
3,634 |
3,344 |
$193K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,078 |
997 |
$178K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
30,488 |
26,759 |
$178K |
| 97116 |
|
13,042 |
6,151 |
$177K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
10,704 |
8,587 |
$174K |
| 72100 |
|
4,230 |
4,074 |
$174K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
6,128 |
5,052 |
$172K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
3,854 |
3,717 |
$164K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
98,731 |
76,622 |
$160K |
| 73140 |
|
1,350 |
1,313 |
$159K |
| 73562 |
|
3,504 |
2,863 |
$159K |
| 76641 |
|
2,640 |
2,066 |
$158K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
179 |
134 |
$154K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
627 |
584 |
$154K |
| 87653 |
|
3,504 |
3,432 |
$142K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
4,727 |
4,596 |
$138K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
1,129 |
1,075 |
$137K |
| 93880 |
|
654 |
623 |
$136K |
| 73560 |
|
2,703 |
2,412 |
$131K |
| 76536 |
|
1,446 |
1,410 |
$130K |
| G0378 |
Hospital observation service, per hour |
14,293 |
8,484 |
$127K |
| 72141 |
|
236 |
227 |
$121K |
| 73090 |
|
1,066 |
1,017 |
$117K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
2,603 |
2,443 |
$113K |
| 72040 |
|
1,756 |
1,677 |
$111K |
| 84443 |
Thyroid stimulating hormone (TSH) |
23,192 |
21,793 |
$110K |
| 87210 |
|
2,507 |
2,378 |
$110K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
16,787 |
14,753 |
$106K |
| 93299 |
|
423 |
417 |
$102K |
| 97162 |
|
2,892 |
2,699 |
$100K |
| 94618 |
|
1,851 |
1,793 |
$98K |
| 87340 |
|
6,263 |
5,866 |
$98K |
| 73080 |
|
1,250 |
1,191 |
$98K |
| 12011 |
|
480 |
465 |
$95K |
| 93925 |
|
1,040 |
1,009 |
$92K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
4,460 |
4,325 |
$86K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
13,639 |
4,419 |
$86K |
| 73502 |
|
2,271 |
2,140 |
$85K |
| 81003 |
|
3,241 |
2,921 |
$83K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
19,569 |
16,806 |
$80K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
17,720 |
12,328 |
$78K |
| 76770 |
|
871 |
844 |
$74K |
| 70486 |
|
624 |
594 |
$72K |
| 73590 |
|
1,467 |
1,334 |
$72K |
| 80074 |
|
1,579 |
1,476 |
$65K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
1,943 |
1,897 |
$60K |
| 72050 |
|
761 |
736 |
$57K |
| A9597 |
Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified |
415 |
393 |
$56K |
| 86762 |
|
4,875 |
4,554 |
$55K |
| 98960 |
|
767 |
754 |
$55K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
6,186 |
5,596 |
$54K |
| 97161 |
|
2,425 |
2,254 |
$54K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
19,697 |
14,375 |
$54K |
| 77062 |
|
257 |
249 |
$52K |
| 92508 |
Group treatment of speech, language, voice, communication, and/or auditory processing disorder |
1,189 |
447 |
$51K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
1,843 |
1,595 |
$51K |
| 97535 |
Self-care/home management training, each 15 minutes |
8,629 |
4,898 |
$50K |
| 10060 |
|
298 |
282 |
$50K |
| 93458 |
|
464 |
420 |
$48K |
| 88142 |
|
7,756 |
7,401 |
$48K |
| 97166 |
|
1,729 |
1,550 |
$48K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
156 |
154 |
$47K |
| 76775 |
|
773 |
736 |
$45K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
2,996 |
2,811 |
$41K |
| 95816 |
|
252 |
239 |
$40K |
| 87807 |
|
943 |
933 |
$38K |
| 77066 |
Tomosynthesis, mammo |
680 |
657 |
$37K |
| 93017 |
|
2,536 |
2,448 |
$36K |
| 97597 |
|
818 |
642 |
$34K |
| 85007 |
|
7,033 |
5,670 |
$33K |
| 86850 |
|
9,463 |
8,582 |
$33K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
7,766 |
3,069 |
$33K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
702 |
654 |
$32K |
| 93225 |
|
252 |
235 |
$32K |
| 77061 |
|
215 |
210 |
$31K |
| 72072 |
|
498 |
483 |
$31K |
| 77065 |
Tomosynthesis, mammo |
1,055 |
1,013 |
$30K |
| 85610 |
|
7,653 |
6,742 |
$30K |
| 73221 |
|
50 |
50 |
$30K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
16,434 |
12,416 |
$30K |
| 88304 |
|
789 |
731 |
$29K |
| 71101 |
|
462 |
433 |
$28K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
1,814 |
1,758 |
$28K |
| 86592 |
|
2,261 |
2,165 |
$27K |
| 87641 |
|
2,804 |
2,589 |
$27K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
6,716 |
6,360 |
$27K |
| A9270 |
Non-covered item or service |
36,621 |
19,765 |
$26K |
| 96376 |
|
8,026 |
4,648 |
$26K |
| 80061 |
Lipid panel |
14,374 |
13,708 |
$25K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
994 |
964 |
$25K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
5,599 |
5,413 |
$25K |
| J2704 |
Injection, propofol, 10 mg |
16,150 |
12,777 |
$25K |
| 43235 |
|
1,423 |
1,373 |
$24K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
6,729 |
5,966 |
$23K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
13,703 |
9,215 |
$22K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
221 |
217 |
$21K |
| 84439 |
|
5,654 |
5,314 |
$21K |
| 83516 |
|
793 |
749 |
$21K |
| 99215 |
Prolong outpt/office vis |
761 |
739 |
$20K |
| 97533 |
|
4,293 |
1,998 |
$20K |
| S9152 |
Speech therapy, re-evaluation |
501 |
481 |
$19K |
| 82728 |
|
4,462 |
4,172 |
$19K |
| 82607 |
|
3,432 |
3,255 |
$18K |
| 87505 |
|
282 |
269 |
$18K |
| 84484 |
|
20,779 |
15,422 |
$17K |
| 87420 |
|
1,258 |
1,205 |
$17K |
| 84132 |
|
950 |
688 |
$17K |
| 97016 |
|
129 |
57 |
$17K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
19,038 |
14,743 |
$17K |
| 85027 |
|
13,110 |
10,755 |
$16K |
| 70496 |
|
222 |
206 |
$14K |
| 29581 |
|
595 |
316 |
$14K |
| 97168 |
|
476 |
464 |
$14K |
| 80076 |
|
9,418 |
8,679 |
$14K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
4,531 |
2,735 |
$14K |
| 93242 |
|
92 |
91 |
$13K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
18,394 |
14,937 |
$13K |
| 85379 |
|
4,689 |
4,392 |
$13K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
5,530 |
5,288 |
$13K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
144 |
136 |
$13K |
| 83735 |
|
12,594 |
9,349 |
$13K |
| J1815 |
Injection, insulin, per 5 units |
5,170 |
2,160 |
$12K |
| 76937 |
|
547 |
486 |
$12K |
| 80069 |
|
1,067 |
991 |
$12K |
| 83880 |
|
6,878 |
5,792 |
$12K |
| 12002 |
|
82 |
79 |
$11K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
371 |
348 |
$11K |
| 87040 |
|
5,251 |
4,132 |
$11K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
4,007 |
3,888 |
$11K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
7,368 |
5,418 |
$11K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
9,753 |
9,204 |
$10K |
| 82570 |
|
4,611 |
4,180 |
$10K |
| 92610 |
|
183 |
172 |
$10K |
| 36416 |
|
782 |
577 |
$9K |
| 73552 |
|
294 |
275 |
$9K |
| 86780 |
|
5,264 |
4,899 |
$9K |
| 77334 |
|
183 |
128 |
$9K |
| 74019 |
|
443 |
424 |
$9K |
| J2060 |
Injection, lorazepam, 2 mg |
2,816 |
2,126 |
$9K |
| 80047 |
|
86 |
79 |
$8K |
| 97165 |
|
440 |
409 |
$8K |
| 86140 |
|
4,793 |
4,418 |
$8K |
| 77300 |
|
48 |
40 |
$8K |
| 72170 |
|
235 |
220 |
$8K |
| 83690 |
|
17,063 |
15,060 |
$8K |
| 73521 |
|
225 |
217 |
$8K |
| 87075 |
|
1,787 |
1,682 |
$7K |
| 73700 |
|
52 |
51 |
$7K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
10,836 |
9,198 |
$7K |
| 86431 |
|
757 |
682 |
$7K |
| 77412 |
|
1,122 |
111 |
$7K |
| 84550 |
|
2,753 |
2,415 |
$7K |
| 94726 |
|
1,215 |
1,192 |
$7K |
| 82247 |
|
1,317 |
940 |
$7K |
| 74022 |
|
712 |
665 |
$7K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
391 |
374 |
$7K |
| 99152 |
|
2,443 |
2,218 |
$7K |
| 59025 |
Fetal non-stress test |
76 |
66 |
$7K |
| 82043 |
|
1,289 |
1,269 |
$7K |
| 92607 |
|
94 |
58 |
$7K |
| 82270 |
|
53 |
51 |
$7K |
| 83605 |
|
3,630 |
2,912 |
$6K |
| 69209 |
|
51 |
42 |
$6K |
| 87205 |
|
3,363 |
3,130 |
$6K |
| J3590 |
Unclassified biologics |
2,000 |
1,049 |
$6K |
| 85652 |
|
4,800 |
4,415 |
$6K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
299 |
212 |
$6K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
14,951 |
13,206 |
$6K |
| 83540 |
|
4,134 |
3,882 |
$6K |
| 88307 |
|
532 |
410 |
$5K |
| 76642 |
|
91 |
84 |
$5K |
| 97164 |
|
187 |
175 |
$5K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
6,404 |
5,851 |
$5K |
| 94200 |
|
2,339 |
1,174 |
$5K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
1,970 |
1,895 |
$5K |
| 95012 |
|
518 |
502 |
$5K |
| 83615 |
|
2,734 |
2,313 |
$5K |
| 87081 |
|
288 |
285 |
$5K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
2,346 |
2,113 |
$5K |
| 87150 |
|
106 |
104 |
$5K |
| 86308 |
|
269 |
263 |
$5K |
| 76870 |
|
67 |
64 |
$5K |
| 99406 |
|
1,060 |
929 |
$4K |
| 85014 |
|
2,548 |
1,823 |
$4K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
25 |
13 |
$4K |
| J1940 |
Injection, furosemide, up to 20 mg |
2,223 |
1,174 |
$4K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
2,752 |
2,232 |
$4K |
| 84100 |
|
3,233 |
2,374 |
$4K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
205 |
64 |
$4K |
| 51701 |
|
1,286 |
1,224 |
$4K |
| 82150 |
|
1,216 |
1,142 |
$4K |
| 95811 |
|
16 |
15 |
$4K |
| 80164 |
|
651 |
574 |
$4K |
| 76801 |
|
71 |
66 |
$4K |
| 73660 |
|
58 |
53 |
$3K |
| 84145 |
|
2,160 |
1,784 |
$3K |
| 93351 |
|
15 |
14 |
$3K |
| 86003 |
|
133 |
106 |
$3K |
| 92523 |
|
12 |
12 |
$3K |
| 86901 |
|
10,225 |
9,228 |
$3K |
| 85018 |
|
5,654 |
4,682 |
$3K |
| J3480 |
Injection, potassium chloride, per 2 meq |
701 |
433 |
$3K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
149 |
140 |
$3K |
| 82550 |
|
1,824 |
1,471 |
$2K |
| 78264 |
|
12 |
12 |
$2K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
4,385 |
2,622 |
$2K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
1,070 |
828 |
$2K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
3,684 |
2,931 |
$2K |
| J1644 |
Injection, heparin sodium, per 1000 units |
6,153 |
3,011 |
$2K |
| 83655 |
|
1,542 |
1,527 |
$2K |
| 86038 |
|
1,264 |
1,226 |
$2K |
| 93298 |
|
46 |
42 |
$2K |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
106 |
41 |
$2K |
| 96523 |
|
15 |
12 |
$2K |
| 96367 |
|
1,766 |
1,338 |
$2K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
1,465 |
769 |
$2K |
| J0689 |
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg |
1,159 |
1,029 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
16,541 |
15,589 |
$2K |
| 94729 |
|
2,440 |
2,367 |
$2K |
| 93926 |
|
13 |
12 |
$2K |
| 87186 |
|
10,822 |
9,678 |
$2K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
248 |
222 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,961 |
1,753 |
$2K |
| 86703 |
|
102 |
96 |
$2K |
| 95911 |
|
191 |
190 |
$2K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
651 |
352 |
$2K |
| 84146 |
|
300 |
286 |
$2K |
| 94727 |
|
811 |
784 |
$2K |
| 72070 |
|
26 |
24 |
$2K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
11,625 |
9,272 |
$2K |
| 87493 |
|
45 |
42 |
$1K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
5,480 |
4,189 |
$1K |
| Q9969 |
Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose |
2,216 |
2,110 |
$1K |
| 73060 |
|
14 |
14 |
$1K |
| J2785 |
Injection, regadenoson, 0.1 mg |
1,884 |
1,828 |
$1K |
| 82784 |
|
737 |
669 |
$1K |
| 70498 |
|
227 |
211 |
$1K |
| 90686 |
|
176 |
162 |
$1K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
380 |
279 |
$1K |
| 83550 |
|
3,584 |
3,385 |
$1K |
| 82533 |
|
258 |
189 |
$1K |
| 86803 |
|
3,499 |
3,366 |
$1K |
| 97163 |
|
41 |
41 |
$1K |
| 83970 |
|
792 |
739 |
$1K |
| 97167 |
|
54 |
52 |
$1K |
| 82950 |
|
3,687 |
3,574 |
$1K |
| 94728 |
|
66 |
66 |
$1K |
| 84153 |
|
639 |
614 |
$987.17 |
| 86580 |
|
1,254 |
1,034 |
$972.92 |
| 86900 |
|
9,580 |
8,621 |
$948.72 |
| 76857 |
|
32 |
30 |
$938.27 |
| J0744 |
Injection, ciprofloxacin for intravenous infusion, 200 mg |
179 |
114 |
$920.12 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
308 |
212 |
$916.72 |
| 84156 |
|
2,906 |
2,499 |
$883.15 |
| 87581 |
|
3,887 |
3,782 |
$844.36 |
| 86255 |
|
91 |
91 |
$837.17 |
| 85730 |
|
3,698 |
3,319 |
$828.13 |
| 84402 |
|
181 |
178 |
$813.90 |
| 29125 |
|
206 |
200 |
$761.02 |
| 97755 |
|
26 |
12 |
$716.47 |
| 87428 |
|
12 |
12 |
$662.92 |
| 90715 |
|
1,741 |
1,667 |
$634.41 |
| 82105 |
|
58 |
56 |
$617.70 |
| 87522 |
Neg quan hep c or qual rna |
38 |
37 |
$614.39 |
| 83001 |
|
156 |
153 |
$595.59 |
| 72082 |
|
12 |
12 |
$576.76 |
| 41899 |
Unlisted procedure, dentoalveolar structures |
379 |
352 |
$487.17 |
| 82044 |
|
175 |
168 |
$478.86 |
| J2791 |
Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu |
213 |
209 |
$471.37 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
2,038 |
1,233 |
$462.34 |
| J7999 |
Compounded drug, not otherwise classified |
672 |
591 |
$461.76 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
388 |
333 |
$461.76 |
| 96160 |
|
631 |
622 |
$436.59 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
208 |
192 |
$401.93 |
| 86706 |
|
14 |
12 |
$370.35 |
| 83520 |
|
13 |
12 |
$340.98 |
| 82746 |
|
2,037 |
1,919 |
$339.54 |
| P9021 |
Red blood cells, each unit |
67 |
44 |
$335.62 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
1,486 |
1,366 |
$326.86 |
| 82951 |
|
478 |
470 |
$299.48 |
| 88342 |
|
820 |
674 |
$292.42 |
| C1769 |
Guide wire |
1,638 |
1,459 |
$253.72 |
| 74230 |
|
12 |
12 |
$251.27 |
| 84403 |
|
382 |
370 |
$241.14 |
| 82947 |
|
106 |
98 |
$235.54 |
| J3105 |
Injection, terbutaline sulfate, up to 1 mg |
13 |
12 |
$222.72 |
| 86769 |
|
12 |
12 |
$219.77 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
1,366 |
1,158 |
$218.58 |
| 91200 |
|
17 |
13 |
$207.04 |
| 82140 |
|
221 |
176 |
$168.31 |
| 89051 |
|
12 |
12 |
$154.32 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
697 |
621 |
$150.95 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
1,451 |
1,297 |
$141.94 |
| 82652 |
|
55 |
55 |
$109.00 |
| 82010 |
|
829 |
734 |
$78.87 |
| 97113 |
|
33 |
12 |
$77.93 |
| 82378 |
|
155 |
110 |
$72.86 |
| 86664 |
|
14 |
14 |
$69.81 |
| A9698 |
Non-radioactive contrast imaging material, not otherwise classified, per study |
473 |
455 |
$61.25 |
| 82977 |
|
16 |
12 |
$59.98 |
| 84450 |
|
859 |
756 |
$34.13 |
| 85660 |
|
41 |
37 |
$30.55 |
| 88173 |
|
29 |
25 |
$24.02 |
| 82952 |
|
256 |
253 |
$21.54 |
| 87390 |
|
219 |
206 |
$19.34 |
| 94667 |
|
29 |
26 |
$17.85 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
1,806 |
881 |
$16.94 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
1,773 |
1,633 |
$13.91 |
| 80185 |
|
34 |
26 |
$13.69 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
4,477 |
3,674 |
$4.70 |
| 85045 |
|
185 |
123 |
$4.06 |
| 82248 |
|
854 |
650 |
$3.39 |
| J1630 |
Injection, haloperidol, up to 5 mg |
231 |
187 |
$2.63 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
1,673 |
1,503 |
$0.00 |
| 84481 |
|
384 |
367 |
$0.00 |
| 84460 |
|
919 |
814 |
$0.00 |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
1,056 |
956 |
$0.00 |
| 92611 |
|
12 |
12 |
$0.00 |
| 86235 |
|
71 |
62 |
$0.00 |
| 95028 |
|
34 |
31 |
$0.00 |
| 86200 |
|
13 |
13 |
$0.00 |
| 84520 |
|
410 |
362 |
$0.00 |
| 84630 |
|
37 |
37 |
$0.00 |
| C1760 |
Closure device, vascular (implantable/insertable) |
43 |
42 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
326 |
312 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
226 |
220 |
$0.00 |
| 86923 |
|
824 |
521 |
$0.00 |
| Q9954 |
Oral magnetic resonance contrast agent, per 100 ml |
223 |
103 |
$0.00 |
| J0897 |
Injection, denosumab, 1 mg |
12 |
12 |
$0.00 |
| J2274 |
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg |
67 |
59 |
$0.00 |
| 82785 |
|
63 |
55 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
14 |
12 |
$0.00 |
| 84425 |
|
107 |
105 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
123 |
120 |
$0.00 |
| 84165 |
|
27 |
26 |
$0.00 |
| 93356 |
|
54 |
53 |
$0.00 |
| 86480 |
|
12 |
12 |
$0.00 |
| 47563 |
|
12 |
12 |
$0.00 |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
12 |
12 |
$0.00 |
| J7070 |
Infusion, d5w, 1000 cc |
28 |
13 |
$0.00 |
| A9577 |
Injection, gadobenate dimeglumine (multihance), per ml |
40 |
32 |
$0.00 |
| 74300 |
|
12 |
12 |
$0.00 |
| 88112 |
|
13 |
12 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
38 |
30 |
$0.00 |
| 95909 |
|
14 |
13 |
$0.00 |
| 86665 |
|
14 |
14 |
$0.00 |
| J1953 |
Injection, levetiracetam, 10 mg |
57 |
39 |
$0.00 |
| 86039 |
|
13 |
13 |
$0.00 |
| 86231 |
|
15 |
15 |
$0.00 |
| 86696 |
|
12 |
12 |
$0.00 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
990 |
861 |
$0.00 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
1,970 |
1,686 |
$0.00 |
| 99153 |
Mod sedat endo service >5yrs |
1,032 |
931 |
$0.00 |
| 86225 |
|
84 |
79 |
$0.00 |
| J0456 |
Injection, azithromycin, 500 mg |
136 |
82 |
$0.00 |
| 83002 |
|
14 |
13 |
$0.00 |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
117 |
114 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,145 |
979 |
$0.00 |
| J3360 |
Injection, diazepam, up to 5 mg |
45 |
40 |
$0.00 |
| 36430 |
|
497 |
381 |
$0.00 |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
321 |
312 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
554 |
415 |
$0.00 |
| 29130 |
|
14 |
14 |
$0.00 |
| 86141 |
|
17 |
12 |
$0.00 |
| C9399 |
Unclassified drugs or biologicals |
38 |
28 |
$0.00 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
1,609 |
995 |
$0.00 |
| 80177 |
|
28 |
25 |
$0.00 |
| 86160 |
|
24 |
12 |
$0.00 |
| 83021 |
|
29 |
24 |
$0.00 |
| 86300 |
|
16 |
12 |
$0.00 |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
28 |
26 |
$0.00 |
| J0500 |
Injection, dicyclomine hcl, up to 20 mg |
13 |
13 |
$0.00 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
25 |
25 |
$0.00 |
| J1335 |
Injection, ertapenem sodium, 500 mg |
20 |
12 |
$0.00 |
| 84134 |
|
20 |
13 |
$0.00 |
| 86364 |
|
15 |
15 |
$0.00 |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
70 |
28 |
$0.00 |
| G0379 |
Direct admission of patient for hospital observation care |
14 |
12 |
$0.00 |
| 86258 |
|
15 |
15 |
$0.00 |
| 94668 |
|
35 |
14 |
$0.00 |